<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Immunology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Immunology</journal-title><trans-title-group xml:lang="ru"><trans-title>Russian Journal of Immunology</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1028-7221</issn><issn publication-format="electronic">2782-7291</issn><publisher><publisher-name xml:lang="en">Russian Society of Immunology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">875</article-id><article-id pub-id-type="doi">10.31857/S102872210002391-5</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Immune biomarkers of in-stent restenosis after percutaneous coronary interventions in myocardial infarction and stable angina patients</article-title><trans-title-group xml:lang="ru"><trans-title>Иммуннобиохимические маркеры рестеноза у пациентов с инфарктом миокарда и стабильной стенокардией напряжения после чрескожного коронарного вмешательства</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Grachev</surname><given-names>N. .</given-names></name><name xml:lang="ru"><surname>Грачев</surname><given-names>Н. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Semenikhin</surname><given-names>A. .</given-names></name><name xml:lang="ru"><surname>Семенихин</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Turmova</surname><given-names>E. .</given-names></name><name xml:lang="ru"><surname>Турмова</surname><given-names>Е. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rublev</surname><given-names>V. .</given-names></name><name xml:lang="ru"><surname>Рублев</surname><given-names>В. У.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nazarenko</surname><given-names>S. .</given-names></name><name xml:lang="ru"><surname>Назаренко</surname><given-names>С. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Anohina</surname><given-names>N. .</given-names></name><name xml:lang="ru"><surname>Анохина</surname><given-names>Н. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Pacific State Medical University</institution></aff><aff><institution xml:lang="ru">Тихоокеанский государственный медицинский университет</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Primorye Regional Clinical Hospital № 1</institution></aff><aff><institution xml:lang="ru">Приморская краевая клиническая больница № 1</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Primorye Regional Clinical Hospital № 1</institution></aff><aff><institution xml:lang="ru">Тихоокеанский государственный медицинский университет</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-07-15" publication-format="electronic"><day>15</day><month>07</month><year>2018</year></pub-date><volume>21</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>255</fpage><lpage>260</lpage><history><date date-type="received" iso-8601-date="2020-10-22"><day>22</day><month>10</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Grachev N..., Semenikhin A..., Turmova E..., Rublev V..., Nazarenko S..., Anohina N...</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, Грачев Н.И., Семенихин А.А., Турмова Е.П., Рублев В.У., Назаренко С.А., Анохина Н.Е.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Grachev N..., Semenikhin A..., Turmova E..., Rublev V..., Nazarenko S..., Anohina N...</copyright-holder><copyright-holder xml:lang="ru">Грачев Н.И., Семенихин А.А., Турмова Е.П., Рублев В.У., Назаренко С.А., Анохина Н.Е.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://rusimmun.ru/jour/article/view/875">https://rusimmun.ru/jour/article/view/875</self-uri><abstract xml:lang="en"><p>The study was aimed to assess the prognostic role of infl ammation biomarkers to evaluate the risk for restenosis in myocardial infarction and stable angina patients undergoing percutaneous coronary intervention. The blood samples were tested immediately before and 7 days after percutaneous coronary intervention for IFN-γ, IL-6, IL-8, IL-17, TNF-α, TNF-β, TGF-β1 and TGF-β2. The key predictors of restenosis after percutaneous coronary intervention during one year were abnormal rates of IFN-γ pre-PCI (OR=5,21) and 7 days after (OR=3,84), IL-6 pre-PCI (OR=1,59), IL-8 pre-PCI (OR=1,73), IL-17 pre- PCI (OR=3,07) and 7 days after (OR=2,34), TNF-α pre-PCI (OR=1,88), TNF-β pre-PCI (OR=1,98) and growth factors: TGF-β1 7 days after PCI (OR=1,82) and TGF-β2 7 days after PCI (OR=2,04).</p></abstract><trans-abstract xml:lang="ru"><p>Исследование было направлено на оценку прогностической роли биомаркеров воспаления для оценки риска рестеноза у пациентов при инфаркте миокарда и со стабильной стенокардией, подвергшихся чрескожному коронарному вмешательству. Забор крови выполнялся непосредственно перед и через 7 дней после ЧКВ для определения ИФН-γ, ИЛ-6, ИЛ-8, ИЛ-17, ФНО-α, ФНО-β, ТФР-β1 и ТФР-β2. Проведен множественный логистический анализ, который выявил предикторы развития рестеноза через 12 месяцев у пациентов после ЧКВ: ИФН-γ до ЧКВ (OR = 5,21) и 7 день после (OR = 3,84), ИЛ-6 до-ЧКВ (OR = 1,59), ИЛ-8 до ЧКВ (OR = 1,73), ИЛ-17 до ЧКВ (OR = 3,07) и 7 день после (OR = 2,34), ФНО-α до ЧКВ (OR = 1,88), ФНО-β до ЧКВ (OR = 1,98) и факторы роста: ТФР-β1 через 7 дней после ЧКВ (OR = 1,82) и ТФР-β2 через 7 дней после ЧКВ (OR = 2,04).</p></trans-abstract><kwd-group xml:lang="ru"><kwd>cytokines</kwd><kwd>percutaneus coronary intervention</kwd><kwd>myocardial infarction</kwd><kwd>stable angina</kwd><kwd>restenosis</kwd><kwd>цитокины</kwd><kwd>чрескожное коронарное вмешательство</kwd><kwd>инфаркт миокарда</kwd><kwd>стенокардия</kwd><kwd>рестеноз</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Силаев А. А., Турмова Е. П., Маркелова Е. В. Анализ эффективности цитокинотерапии в послеоперационном периоде у пациентов с коронарным атеросклерозом. Тихоокеанский медицинский журнал 2013, 3, 18–21.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Toutouzas K., Colombo A., Stefanadis C. Infl ammation and restenosis after percutaneous coronary interventions. European heart journal 2004, 25(19), 1679–1687.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Byrne R. A., Joner M., Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC2014. European heart journal 2015, 36(47), 3320–3331.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Okamoto E. I., Couse T., De Leon H., et al. Perivascular infl ammation after balloon angioplasty of porcine coronary arteries. Circulation 2001, 104(18), 2228–2235.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Chrobak I., Lenna S., Stawski L., Trojanowska M. Interferon- γ promotes vascular remodeling in human microvascular endothelial cells by upregulating endothelin (ET)-1 and transforming growth factor (TGF) β2. Journal of cellular physiology 2013, 228(8), 1774–1783.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Szkodzinski J., Blazelonis A., Wilczek K., et al. The role of interleukin-6 and transforming growth factor-β1 in predicting restenosis within stented infarct-related artery. International journal of immunopathology and pharmacology 2009, 22(2), 493–500.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Eyüboğlu M. In stent restenosis after percutaneous coronary intervention. Anatolian journal of cardiology 2016, 16(1), 73.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>heng G., Wei L., Xiurong W., Xiangzhen L., Shiguang Z., Songbin F. IL-17 stimulates migration of carotid artery vascular smooth muscle cells in an MMP-9 dependent manner via p38 MAPK and ERK1/2-dependent NFkappaB and AP-1 activation. Cellular and molecular neurobiology 2009, 29(8), 1161–1168.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Monraats P. S., Pires N. M., Schepers A., et al. Tumor necrosis factor-alpha plays an important role in restenosis development. FASEB journal: offi cial publication of the Federation of American Societies for Experimental Biology 2005, 19(14), 1998–2004.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Koch W., Tiroch K., von Beckerath N., Schömig A., Kastrati A. Tumor necrosis factor-α, lymphotoxin-α, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. Cytokine 2003, 24(4), 161–171.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Zhao W., Wang C., Liu R., et al. Eff ect of TGF-β1 on the migration and recruitment of mesenchymal stem cells after vascular balloon injury: involvement of matrix metalloproteinase-14. Scientifi c reports 2016, 6, 21176.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Joviliano E. E., Piccinato C. E., Dellalibera-Joviliano R., Moriya T., Évora P. R. Infl ammatory markers and restenosis in peripheral percutaneous angioplasty with intravascular stenting: current concepts. Annals of vascular surgery 2011, 25(6), 846–855.</mixed-citation></ref></ref-list></back></article>
